Inhibitory effect of gallic acid on advanced glycation end products induced up-regulation of inflammatory cytokines and matrix proteins in H9C2 (2-1) cells

Cardiovascular Toxicology

Volumn 13, Issue 4, 2013, Pages 396-405

  Umadevi, Subramanian ^a   Gopi, Venkatachalam ^a   Vellaichamy, Elangovan ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

Advanced glycation end products; Fibrotic marker genes; Gallic acid; Oxidative stress; RAGE

Indexed keywords

ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CYTOKINE; GALLIC ACID; GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; MATRIX PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUTRALIZING ANTIBODY; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CARDIAC MYOFIBROBLAST; CONTROLLED STUDY; HEART PROTECTION; IN VITRO STUDY; INCUBATION TIME; LONG TERM EXPOSURE; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; UPREGULATION;

ANIMALS; CELL LINE; CELLS, CULTURED; CYTOKINES; EXTRACELLULAR MATRIX PROTEINS; GALLIC ACID; GLYCOSYLATION END PRODUCTS, ADVANCED; INFLAMMATION MEDIATORS; RATS; REACTIVE OXYGEN SPECIES; UP-REGULATION;

EID: 84890513699     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-013-9222-2     Document Type: Article

References (54)

1. Thornalley, J. P. (1996). Advanced glycation and the development of diabetic complications: Unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrinology and Metabolism-London, 3, 149-166.
2. Singh, R.; Barden, A.; Mori, T.; & Beilin, L. (2001). Advanced glycation end-products: A review. Diabetologia, 44, 129-146.
3. Aronson, D. (2003). Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. Journal of Hypertension, 21, 3-12.
4. Thallas-Bonke, V.; Lindschau, C.; Rizkalla, B.; Bach, L. A.; Boner, G.; Meier, M.; et al. (2004). Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes, 53, 2921-2930.
5. Corman, B.; Duriez, M.; Poitevin, P.; Heudes, D.; Bruneval, P.; Tedgui, A.; et al. (1998). Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proceedings of the National Academy of Sciences of the United States of America, 95, 1301-1306.
6. Hartog, J. W.; Voors, A. A.; Bakker, S. J.; Smit, A. J.; & van Veldhuisen, D. J. (2007). Advanced glycation end-products (AGEs) and heart failure: Pathophysiology and clinical implications. European Journal of Heart Failure, 9, 1146-1155.
7. Huang, J. S.; Guh, J. Y.; Hung, W. C.; Yang, M. L.; Lai, Y. H.; Chen, H. C.; et al. (1999). Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells. The Biochemical Journal, 342(Pt 1), 231-238.
8. Lohwasser, C.; Neureiter, D.; Popov, Y.; Bauer, M.; & Schuppan, D. (2009). Role of the receptor for advanced glycation end products in hepatic fibrosis. World Journal of Gastroenterology, 15, 5789-5798.
9. Bierhaus, A.; Chevion, S.; Chevion, M.; Hofmann, M.; Quehenberger, P.; Illmer, T.; et al. (1997). Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes, 46, 1481-1490.
10. Schmidt, A. M.; Mora, R.; Cao, R.; Yan, S. D.; Brett, J.; Ramakrishnan, R.; et al. (1994). The endothelial cell binding site for advanced glycation end products consists of a complex: An integral membrane protein and a lactoferrin-like polypeptide. The Journal of Biological Chemistry, 269, 9882-9888.
11. Lander, H. M.; Tauras, J. M.; Ogiste, J. S.; Hori, O.; Moss, R. A.; & Schmidt, A. M. (1997). Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. The Journal of Biological Chemistry, 272, 17810-17814.
12. Stern, D.; Yan, S. D.; Yan, S. F.; & Schmidt, A. M. (2002). Receptor for advanced glycation endproducts: A multiligand receptor magnifying cell stress in diverse pathologic settings. Advanced Drug Delivery Reviews, 54, 1615-1625.
13. Jagan, S.; Ramakrishnan, G.; Anandakumar, P.; Kamaraj, S.; & Devaki, T. (2008). Antiproliferative potential of gallic acid against diethylnitrosamine-induced rat hepatocellular carcinoma. Molecular and Cellular Biochemistry, 319, 51-59.
14. Pal, C.; Bindu, S.; Dey, S.; Alam, A.; Goyal, M.; Iqbal, M. S.; et al. (2010). Gallic acid prevents nonsteroidal anti-inflammatory drug-induced gastropathy in rat by blocking oxidative stress and apoptosis. Free Radical Biology and Medicine, 49, 258-267.
15. Priscilla, D. H.; & Prince, P. S. (2009). Cardioprotective effect of gallic acid on cardiac troponin-T, cardiac marker enzymes, lipid peroxidation products and antioxidants in experimentally induced myocardial infarction in Wistar rats. Chemico-Biological Interactions, 179, 118-124.
16. Umadevi, S.; Gopi, V.; Simna, S. P.; Parthasarathy, A.; Yousuf, S. M.; & Elangovan, V. (2012). Studies on the cardio protective role of gallic acid against AGE-induced cell proliferation and oxidative stress in H9C2 (2-1) cells. Cardiovascular Toxicology, 12, 304-311.
17. Andreea, S. I.; Marieta, C.; & Anca, D. (2008). AGEs and glucose levels modulate type I and III procollagen mRNA synthesis in dermal fibroblasts cells culture. Experimental Diabetes Research, 2008, 473603.
18. Stathopoulou, K.; Beis, I.; & Gaitanaki, C. (2008). MAPK signaling pathways are needed for survival of H9c2 cardiac myoblasts under extracellular alkalosis. American Journal of Physiology, Heart and Circulatory Physiology, 295, H1319-H1329.
19. Lee, H. B.; Yu, M. R.; Yang, Y.; Jiang, Z.; & Ha, H. (2003). Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. Journal of the American Society of Nephrology, 14, S241-S245.
20. Pamplona, R. (2008). Membrane phospholipids, lipoxidative damage and molecular integrity: a causal role in aging and longevity. Biochimica et Biophysica Acta, 1777, 1249-1262.
21. Ambati, J.; Ambati, B. K.; Yoo, S. H.; Ianchulev, S.; & Adamis, A. P. (2003). Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies. Survey of Ophthalmology, 48, 257-293.
22. Lee, S. J.; & Lee, K. W. (2007). Protective effect of (-)-epigallocatechin gallate against advanced glycation endproducts-induced injury in neuronal cells. Biological and Pharmaceutical Bulletin, 30, 1369-1373.
23. Nakagawa, T.; Yokozawa, T.; Terasawa, K.; Shu, S.; & Juneja, L. R. (2002). Protective activity of green tea against free radical- and glucose-mediated protein damage. Journal of Agricultural and Food Chemistry, 50, 2418-2422.
24. Peters, C. A.; Freeman, M. R.; Fernandez, C. A.; Shepard, J.; Wiederschain, D. G.; & Moses, M. A. (1997). Dysregulated proteolytic balance as the basis of excess extracellular matrix in fibrotic disease. The American Journal of Physiology, 272, R1960-R1965.
25. Steed, M. M.; Tyagi, N.; Sen, U.; Schuschke, D. A.; Joshua, I. G.; & Tyagi, S. C. (2010). Functional consequences of the collagen/elastin switch in vascular remodeling in hyperhomocysteinemic wild-type, eNOS-/-, and iNOS-/- mice. American journal of physiology, Lung Cellular and Molecular Physiology, 299, L301-L311.
26. Camelliti, P.; Borg, T. K.; & Kohl, P. (2005). Structural and functional characterisation of cardiac fibroblasts. Cardiovascular Research, 65, 40-51.
27. Death, A. K.; Fisher, E. J.; McGrath, K. C.; & Yue, D. K. (2003). High glucose alters matrix metalloproteinase expression in two key vascular cells: Potential impact on atherosclerosis in diabetes. Atherosclerosis, 168, 263-269.
28. Tarallo, S.; Beltramo, E.; Berrone, E.; Dentelli, P.; & Porta, M. (2010). Effects of high glucose and thiamine on the balance between matrix metalloproteinases and their tissue inhibitors in vascular cells. Acta Diabetologica, 47, 105-111.
29. Thallas-Bonke, V.; Thorpe, S. R.; Coughlan, M. T.; Fukami, K.; Yap, F. Y.; Sourris, K. C.; et al. (2008). Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes, 57, 460-469.
30. Li, J. H.; Huang, X. R.; Zhu, H. J.; Johnson, R.; & Lan, H. Y. (2003). Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney International, 63, 2010-2019.
31. Ihn, H. (2002). Pathogenesis of fibrosis: Role of TGF-beta and CTGF. Current Opinion in Rheumatology, 14, 681-685.
32. Khan, R.; & Sheppard, R. (2006). Fibrosis in heart disease: Understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology, 118, 10-24.
33. Lassegue, B.; & Clempus, R. E. (2003). Vascular NAD(P)H oxidases: Specific features, expression, and regulation. American Journal of Physiology, Regulatory, Integrative and Comparative Physiology, 285, R277-R297.
34. Sangle, G. V.; Zhao, R.; Mizuno, T. M.; & Shen, G. X. (2010). Involvement of RAGE, NADPH oxidase, and Ras/Raf-1 pathway in glycated LDL-induced expression of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular endothelial cells. Endocrinology, 151, 4455-4466.
35. Bedard, K.; & Krause, K. H. (2007). The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiological Reviews, 87, 245-313.
36. San Martin, A.; Foncea, R.; Laurindo, F. R.; Ebensperger, R.; Griendling, K. K.; & Leighton, F. (2007). Nox1-based NADPH oxidase-derived superoxide is required for VSMC activation by advanced glycation end-products. Free Radical Biology and Medicine, 42, 1671-1679.
37. Zafari, A. M.; Ushio-Fukai, M.; Akers, M.; Yin, Q.; Shah, A.; Harrison, D. G.; et al. (1998). Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension, 32, 488-495.
38. Pacher, P.; Beckman, J. S.; & Liaudet, L. (2007). Nitric oxide and peroxynitrite in health and disease. Physiological Reviews, 87, 315-424.
39. Ricciardolo, F. L.; Sterk, P. J.; Gaston, B.; & Folkerts, G. (2004). Nitric oxide in health and disease of the respiratory system. Physiological Reviews, 84, 731-765.
40. Gao, X.; Belmadani, S.; Picchi, A.; Xu, X.; Potter, B. J.; Tewari-Singh, N.; et al. (2007). Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice. Circulation, 115, 245-254.
41. Csiszar, A.; & Ungvari, Z. (2008). Endothelial dysfunction and vascular inflammation in type 2 diabetes: Interaction of AGE/RAGE and TNF-alpha signaling. American Journal of Physiology, Heart and Circulatory Physiology, 295, H475-H476.
42. Mamputu, J. C.; & Renier, G. (2004). Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: Inhibitory effect of antioxidants. Journal of Leukocyte Biology, 75, 1062-1069.
43. Brownlee, M. (1995). Advanced protein glycosylation in diabetes and aging. Annual Review of Medicine, 46, 223-234.
44. Brownlee, M.; Cerami, A.; & Vlassara, H. (1988). Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. The New England journal of medicine, 318, 1315-1321.
45. Park, S.; Yoon, S. J.; Tae, H. J.; & Shim, C. Y. (2011). RAGE and cardiovascular disease. Frontiers in Bioscience: A Journal and Virtual Library, 16, 486-497.
46. Forbes, J. M.; Coughlan, M. T.; & Cooper, M. E. (2008). Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes, 57, 1446-1454.
47. Brasier, A. R. (2010). The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovascular Research, 86, 211-218.
48. Frier, B. C.; Noble, E. G.; & Locke, M. (2008). Diabetes-induced atrophy is associated with a muscle-specific alteration in NF-kappaB activation and expression. Cell Stress and Chaperones, 13, 287-296.
49. Van der Heiden, K.; Cuhlmann, S.; le Luong, A.; Zakkar, M.; & Evans, P. C. (2010). Role of nuclear factor kappaB in cardiovascular health and disease. Clinical Science, 118, 593-605. (London, England: 1979).
50. Evans, J. L.; Goldfine, I. D.; Maddux, B. A.; & Grodsky, G. M. (2002). Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of type 2 diabetes. Endocrine Reviews, 23, 599-622.
51. Zhang, W.; & Liu, H. T. (2002). MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Research, 12, 9-18.
52. Roux, P. P.; & Blenis, J. (2004). ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiology and Molecular Biology Reviews, 68, 320-344.
53. Oeckinghaus, A.; Hayden, M. S.; & Ghosh, S. (2011). Crosstalk in NF-kappaB signaling pathways. Nature Immunology, 12, 695-708.
54. Li, S. Y.; Sigmon, V. K.; Babcock, S. A.; & Ren, J. (2007). Advanced glycation endproduct induces ROS accumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in human cardiac myocytes. Life Sciences, 80, 1051-1056.